Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q1

3341.TEDINET S100OZY9
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥71.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥936m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥993m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥993m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥427m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥427m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥195.3bnat 2022-06-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥199.1bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2022-06-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥49.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.5bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.272021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥1.7bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥278m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.2bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥451m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥77.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥71.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
Net salesPrior1YTDDuration71851000000JPY
Net salesCurrentYTDDuration74709000000JPY
Cost of salesPrior1YTDDuration59380000000JPY
Cost of salesCurrentYTDDuration61928000000JPY
Gross profitPrior1YTDDuration12471000000JPY
Gross profitCurrentYTDDuration12780000000JPY
Selling general and administrative expensesPrior1YTDDuration11534000000JPY
Selling general and administrative expensesCurrentYTDDuration11888000000JPY
Operating incomePrior1YTDDuration936000000JPY
Operating incomeCurrentYTDDuration892000000JPY
Commission fee noiPrior1YTDDuration9000000JPY
Commission fee noiCurrentYTDDuration9000000JPY
Rent income noiPrior1YTDDuration124000000JPY
Rent income noiCurrentYTDDuration142000000JPY
Insurance income noiPrior1YTDDuration130000000JPY
Insurance income noiCurrentYTDDuration40000000JPY
Subsidy income noiPrior1YTDDuration29000000JPY
Subsidy income noiCurrentYTDDuration17000000JPY
Other noiPrior1YTDDuration56000000JPY
Other noiCurrentYTDDuration62000000JPY
Non operating incomePrior1YTDDuration350000000JPY
Non operating incomeCurrentYTDDuration271000000JPY
Interest expenses noePrior1YTDDuration79000000JPY
Interest expenses noeCurrentYTDDuration64000000JPY
Rent expense noePrior1YTDDuration93000000JPY
Rent expense noeCurrentYTDDuration107000000JPY
Other noePrior1YTDDuration119000000JPY
Other noeCurrentYTDDuration78000000JPY
Non operating expensesPrior1YTDDuration293000000JPY
Non operating expensesCurrentYTDDuration250000000JPY
Ordinary incomePrior1YTDDuration993000000JPY
Ordinary incomeCurrentYTDDuration913000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration0JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration11000000JPY
Extraordinary incomePrior1YTDDuration0JPY
Extraordinary incomeCurrentYTDDuration11000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration－JPY
Loss on sales of noncurrent assets elCurrentYTDDuration0JPY
Extraordinary lossPrior1YTDDuration－JPY
Extraordinary lossCurrentYTDDuration0JPY
Income before income taxesPrior1YTDDuration993000000JPY
Income before income taxesCurrentYTDDuration925000000JPY
Income taxes currentPrior1YTDDuration1182000000JPY
Income taxes currentCurrentYTDDuration888000000JPY
Income taxes deferredPrior1YTDDuration-616000000JPY
Income taxes deferredCurrentYTDDuration-354000000JPY
Income taxesPrior1YTDDuration565000000JPY
Income taxesCurrentYTDDuration534000000JPY
Profit lossPrior1YTDDuration427000000JPY
Profit lossCurrentYTDDuration391000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass